Annual Report Review Page Header.jpg
Annual Report Page thumbnail.jpg

BBI Solutions Annual Report 2020

Serving the Science of Diagnostics

Amid a global pandemic and considerable challenges for all, 2020 was a year of significant growth for BBI Solutions. We were delighted to continue our progress and consolidate our position as a leading global diagnostics provider. We achieved this through acquisition, organic growth, strategic partnerships, innovation, NPD and substantial capital investment. A highlight of 2020 was the acquisition of DIARECT AG and their world-leading recombinant autoimmune antigen capability, which immediately enhanced BBI's portfolio and position as a 'complete' immunoassay reagent supplier'.

BBI Solutions also played a pivotal role in the global response to the SARS CoV-2 challenge when we were chosen to be a member of 'The UK Government Rapid Test Consortium' (UK-RTC), a select group of industry leaders invested in the development of the rapid antibody tests for Covid-19. Our app development team also developed a new mobile feature using our patented Novarum™️ technology to facilitate creating and sharing digital Covid test certificates, supporting employers, travel providers, and the safe reopening of venues and events globally.

BBI Solutions create value by using our scientific innovation, world-class facilities and commercial responsiveness to serve the in-vitro diagnostic industry. We provide immunodiagnostic reagents and individual test components to our diagnostics customers, while also offering solutions that bring these components together in complete laboratory or point-of-care tests.

For our employees,  we have developed a working environment and culture where they can progress their careers serving the science of diagnostics,and contribute towards providing healthcare on a global stage.


 

Message from our Chairman, Alan Peterson, OBE

Alan Peterson, Chairman, BBI Solutions

Welcome to the BBI Solutions Annual Review for 2020. It is not a mandatory requirement for a privately owned company to produce an annual review, but the company has developed and matured to the extent that we judge such a publication would be useful.

We are delighted to be able to share the review with you and showcase how we are serving the science of diagnostics by delivering value through innovation, partnership and effective delivery.

 

Message from Dr. Mario Gualano, CEO


Mario Gualano, CEO, BBI Solutions

Over the last few years, we have transformed our business through a combination of strategic investment and focused leadership. We are very proud to have an international in-market sales force supported by industry-leading scientists, facilities and systems – quite a platform. These have allowed us to grow our global revenue, establish a culture of continuous improvement, and achieve sustainable productivity improvements.

I look forward to the future growth of BBI Solutions as we continue in our mission of serving the science of diagnostics across the globe.


 

Growth Drivers for BBI Solutions

  • Attractive end markets with stable long-term growth
  • Diversified product portfolio and working with the world’s leading IVD companies
  • Well-invested, scalable global platform
  • Strong financial performance with a high level of recurring revenue
  • Well positioned due to process know-how, regulation and products embedded in customer solutions
  • Strong growth outlook including highly complementary strategic acquisitions
  • Enhanced and highly experienced management team
  • 13% of our employees have MSc
  • Over 60% of our employees have degrees
  • 5% of our employees are PhDs

 

Download the BBI Solutions Annual Report 2020

 (please click the image below to view/download the English or German Language version)

BBI Solutions Annual Review 2020

 


 

Questions

If you have any questions or require further information please contact our Customer Services Team directly who will be happy to assist on  tel:+44 (0) 1495 363000 or alternatively you can submit an enquiry here.

BBI Solutions Brands

diarect.png

The acquisition of DIARECT in June 2020 and their world leading recombinant autoimmune antigen capability immediately enhances BBI’s portfolio and position as a ‘complete’ immunoassay reagent supplier. This further enhances BBI’s position as the world’s largest diagnostics components company with a market leading antigen portfolio.

mbs.png

Maine Biotechnology Services brings 27 years of knowledge, experience, process development, and project management to our customers to ensure the best possible antibodies for any application. As antibody development goals in the biotechnology and pharmaceutical industry have evolved the acquisition of MBS will help BBI further meet and exceed our customers needs.

Newsletter

Signup for our newsletter to receive the latest BBI Solutions updates and special offers in your inbox